| 000 | 01817 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517114658.0 | ||
| 264 | 0 | _c20171024 | |
| 008 | 201710s 0 0 eng d | ||
| 022 | _a1868-8500 | ||
| 024 | 7 |
_a10.1007/s12672-016-0273-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKroiss, Matthias | |
| 245 | 0 | 0 |
_aDrug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. _h[electronic resource] |
| 260 |
_bHormones & cancer _c12 2016 |
||
| 300 |
_a345-355 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdrenal Cortex Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aAdrenocortical Carcinoma _xdrug therapy |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xpharmacology |
| 650 | 0 | 4 |
_aBortezomib _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEndoplasmic Reticulum Stress _xdrug effects |
| 650 | 0 | 4 |
_aEndoribonucleases _xgenetics |
| 650 | 0 | 4 |
_aEukaryotic Initiation Factor-2 _xmetabolism |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeupeptins _xpharmacology |
| 650 | 0 | 4 |
_aMitotane _xpharmacology |
| 650 | 0 | 4 |
_aOligopeptides _xpharmacology |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aProteasome Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aProtein Serine-Threonine Kinases _xgenetics |
| 650 | 0 | 4 |
_aX-Box Binding Protein 1 _xgenetics |
| 700 | 1 | _aSbiera, Silviu | |
| 700 | 1 | _aKendl, Sabine | |
| 700 | 1 | _aKurlbaum, Max | |
| 700 | 1 | _aFassnacht, Martin | |
| 773 | 0 |
_tHormones & cancer _gvol. 7 _gno. 5-6 _gp. 345-355 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s12672-016-0273-2 _zAvailable from publisher's website |
| 999 |
_c26421569 _d26421569 |
||